AU2001244713A1 - Transporters and drug delivery system by using the same - Google Patents
Transporters and drug delivery system by using the sameInfo
- Publication number
- AU2001244713A1 AU2001244713A1 AU2001244713A AU4471301A AU2001244713A1 AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1 AU 2001244713 A AU2001244713 A AU 2001244713A AU 4471301 A AU4471301 A AU 4471301A AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1
- Authority
- AU
- Australia
- Prior art keywords
- transporters
- same
- delivery system
- drug delivery
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012377 drug delivery Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000101113 | 2000-04-03 | ||
| JP2001-56912 | 2001-03-01 | ||
| JP2001056912 | 2001-03-01 | ||
| JP2000-101113 | 2001-03-01 | ||
| PCT/JP2001/002882 WO2001074400A1 (en) | 2000-04-03 | 2001-04-03 | Transporters and drug delivery system by using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001244713A1 true AU2001244713A1 (en) | 2001-10-15 |
Family
ID=26589355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001244713A Abandoned AU2001244713A1 (en) | 2000-04-03 | 2001-04-03 | Transporters and drug delivery system by using the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7455855B2 (en) |
| EP (1) | EP1279406A4 (en) |
| KR (1) | KR100777195B1 (en) |
| CN (1) | CN100479862C (en) |
| AU (1) | AU2001244713A1 (en) |
| CA (1) | CA2404737C (en) |
| WO (1) | WO2001074400A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100777195B1 (en) | 2000-04-03 | 2007-11-19 | 산텐 세이야꾸 가부시키가이샤 | Delivery material and drug delivery system using the same |
| US20040254197A1 (en) * | 2001-09-28 | 2004-12-16 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethlene glycol |
| US7279150B2 (en) * | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| EP1498420B1 (en) | 2002-03-29 | 2017-02-01 | Nof Corporation | Phospholipid derivative |
| JP4808403B2 (en) * | 2002-09-30 | 2011-11-02 | 日油株式会社 | Phospholipid derivative |
| JP4403303B2 (en) | 2003-01-06 | 2010-01-27 | 日油株式会社 | Phospholipid derivative and method for producing the same |
| JP4526479B2 (en) | 2003-03-20 | 2010-08-18 | 日油株式会社 | Phospholipid derivative |
| CA2705785A1 (en) * | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2370110B1 (en) | 2008-12-25 | 2017-08-02 | Canon Kabushiki Kaisha | Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method |
| EP2600900A4 (en) | 2010-08-06 | 2014-11-19 | Univ Illinois | MULTIPLEXED SUPRAMOLECULAR ASSEMBLIES FOR NON-VIRAL ADMINISTRATION OF GENETIC MATERIAL |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS |
| JP7057290B2 (en) | 2016-06-27 | 2022-04-19 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Quinazoline and indole compounds for the treatment of medical disorders |
| WO2018160889A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
| KR20210018199A (en) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | Cerevlon binder for decomposition of Ikaros |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| MA55628A (en) | 2019-04-12 | 2022-02-16 | C4 Therapeutics Inc | TRICYCLIC DEGRADING AGENTS OF IKAROS AND AIOLOS |
| JP2023515073A (en) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | Heteroaryl compounds for the treatment of complement factor D-mediated disorders |
| KR20220166797A (en) | 2020-03-05 | 2022-12-19 | 씨4 테라퓨틱스, 인코포레이티드 | Compounds for targeted degradation of BRD9 |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| FR2660193B1 (en) * | 1990-04-03 | 1994-11-04 | Philippe Maincent | OPTHALMIC PRODUCT COMPRISING NANOCAPSULES, PROCESS FOR THE PREPARATION AND USE OF NANOCAPSULES. |
| DE4120760A1 (en) | 1991-06-24 | 1993-03-04 | 3 M Medica Gmbh | CARRIER SYSTEMS FOR MEDICINAL PRODUCTS |
| WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| CA2137297C (en) * | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Reactive vesicle and functional substance-fixed vesicle |
| EP0754046A1 (en) * | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
| JP3525516B2 (en) | 1994-10-27 | 2004-05-10 | 日本油脂株式会社 | Reactive endoplasmic reticulum, endoplasmic reticulum modifier, and production method |
| NZ318472A (en) * | 1995-09-21 | 1999-10-28 | Quadrant Healthcare Uk Ltd | Composition or conjugate containing a gp60 receptor and a transcytosis enhancer (typically albumin) |
| US5641750A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6071532A (en) * | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| EP1920773B1 (en) * | 1996-11-05 | 2011-01-05 | The Children's Medical Center Corporation | Thalidomide and dexamethasone for the treatment of tumors |
| US6258351B1 (en) * | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| DK1053012T3 (en) | 1998-02-09 | 2003-11-17 | Enzon Pharmaceuticals Inc | Pharmaceutical compositions comprising PEG asparaginase for the treatment of HIV infections |
| IL138221A0 (en) | 1998-03-26 | 2001-10-31 | Schering Corp | Formulations for protection of peg-interferon alpha conjugates |
| HU226294B1 (en) | 1998-08-06 | 2008-08-28 | Mountain View Pharmaceuticals | Peg-urate oxidase conjugates and use thereof |
| DE69938148T2 (en) | 1998-12-18 | 2009-02-26 | Alza Corp., Mountain View | METHOD FOR ADMINISTERING A CONNECTION TO MULTIPLE RESISTANT CELLS |
| JP2002539082A (en) | 1999-02-08 | 2002-11-19 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Vascular endothelial growth factor 2 |
| NZ514990A (en) | 1999-04-23 | 2004-01-30 | Alza Corp | Releasable linkage and compositions containing same |
| US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
| EP2845596A3 (en) | 2000-01-10 | 2015-07-15 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
| WO2001062827A2 (en) * | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| KR100777195B1 (en) | 2000-04-03 | 2007-11-19 | 산텐 세이야꾸 가부시키가이샤 | Delivery material and drug delivery system using the same |
| US20040254197A1 (en) * | 2001-09-28 | 2004-12-16 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethlene glycol |
| DE10161149B4 (en) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Use of heparin-containing ophthalmic agent |
-
2001
- 2001-04-03 KR KR1020027013171A patent/KR100777195B1/en not_active Expired - Fee Related
- 2001-04-03 US US10/240,438 patent/US7455855B2/en not_active Expired - Fee Related
- 2001-04-03 WO PCT/JP2001/002882 patent/WO2001074400A1/en not_active Ceased
- 2001-04-03 CN CNB018074677A patent/CN100479862C/en not_active Expired - Fee Related
- 2001-04-03 CA CA2404737A patent/CA2404737C/en not_active Expired - Fee Related
- 2001-04-03 EP EP01917801A patent/EP1279406A4/en not_active Withdrawn
- 2001-04-03 AU AU2001244713A patent/AU2001244713A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2404737A1 (en) | 2001-10-11 |
| US20030144247A1 (en) | 2003-07-31 |
| EP1279406A1 (en) | 2003-01-29 |
| CN100479862C (en) | 2009-04-22 |
| CA2404737C (en) | 2010-06-29 |
| US7455855B2 (en) | 2008-11-25 |
| KR100777195B1 (en) | 2007-11-19 |
| KR20030009414A (en) | 2003-01-29 |
| WO2001074400A1 (en) | 2001-10-11 |
| CN1420790A (en) | 2003-05-28 |
| EP1279406A4 (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001244713A1 (en) | Transporters and drug delivery system by using the same | |
| AU2001288388A1 (en) | Substance delivery system | |
| AU2123200A (en) | Drug delivery device | |
| AU4985600A (en) | Drug delivery device | |
| EP1545662B8 (en) | Drug delivery system | |
| AU2001264887A1 (en) | Drug delivery device | |
| AU1719800A (en) | Drug delivery systems and methods | |
| AU2001238386A1 (en) | Medication delivery devices | |
| AU2002244142A1 (en) | Integrated medication delivery system | |
| AU7839900A (en) | Reusable medication delivery device | |
| AU2001235009A1 (en) | Drug delivery apparatus | |
| AU2463701A (en) | Drug delivery system exhibiting permeability control | |
| AU4947100A (en) | Drug delivery device | |
| AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
| AU2001281171A1 (en) | Medication dispensing system | |
| AU4995100A (en) | Selectable agent delivery system | |
| AU3837999A (en) | Drug delivery device | |
| AU2001270963A1 (en) | Transdermal drug delivery system | |
| AU2001260244A1 (en) | Product delivery system | |
| AU6196600A (en) | Medication reminder system | |
| AU2002222138A1 (en) | Drug delivery system | |
| AU2003285550A1 (en) | Drug delivery system | |
| AU2001244854A1 (en) | Local drug delivery | |
| AU2002210580A1 (en) | Drug delivery system | |
| AU2983100A (en) | Drug delivery vehicle |